Table 2.
Patient demographics and baseline clinical characteristics
| Overall (N = 8) | |
|---|---|
| Age, years | 67.3 (8.7) |
| Male | 6 (75.0) |
| White race | 8 (100.0) |
| Weight, kg | 77.4 (15.9) |
| BMI, kg/m2 | 25.9 (2.8) |
| Time since PD diagnosis, years | 11.3 (5.6) |
| Time since motor fluctuations started, years | 5.9 (3.8) |
| Modified Hoehn and Yahr score when “ON” | 2.4 (0.4) |
| Number of “OFF” episodes per day | 4.0 (1.8) |
| Type of “OFF” episodes experienced | |
| Wearing “OFF” | 7 (87.5) |
| Delayed “ON” | 7 (87.5) |
| Morning akinesia | 6 (75.0) |
| Sudden “OFF” | 6 (75.0) |
| Dose failure | 4 (50.0) |
| Concomitant PD medications | |
| Levodopa-containing agents | 8 (100.0) |
| Dopamine agonists | 7 (87.5) |
| Monoamine oxidase-B inhibitors | 3 (37.5) |
| Amantadine | 1 (12.5) |
| Rivastigmine | 1 (12.5) |
Data are n (%) or mean (SD)
BMI body mass index, PD Parkinson’s disease, SD standard deviation